Cargando…

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial

BACKGROUND: Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are limited data on the time course of changes in forced expiratory volume in 1 s (FEV(1)) preceding the first reported symptom and after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watz, Henrik, Tetzlaff, Kay, Magnussen, Helgo, Mueller, Achim, Rodriguez-Roisin, Roberto, Wouters, Emiel F. M., Vogelmeier, Claus, Calverley, Peter M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293570/ https://www.ncbi.nlm.nih.gov/pubmed/30545350 http://dx.doi.org/10.1186/s12931-018-0944-3

Ejemplares similares

Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease
por: Rodriguez-Roisin, Roberto, et al.
Publicado: (2016)

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline
por: Ferguson, Gary T, et al.
Publicado: (2020)

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study
por: Watz, Henrik, et al.
Publicado: (2014)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Cardiovascular predictors of mortality and exacerbations in patients with COPD
por: Alter, Peter, et al.
Publicado: (2022)

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015)

IgE is associated with exacerbations and lung function decline in COPD
por: Lommatzsch, Marek, et al.
Publicado: (2022)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

COPD: the patient perspective
por: Jones, Paul W, et al.
Publicado: (2016)

Pre–Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel
por: Wouters, Emiel F. M.
Publicado: (2021)

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
por: Singh, Dave, et al.
Publicado: (2020)

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
por: Waschki, Benjamin, et al.
Publicado: (2017)

The Challenges of Spirometric Diagnosis of COPD
por: Maldonado-Franco, Adriana, et al.
Publicado: (2023)

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans
por: Kahnert, Kathrin, et al.
Publicado: (2018)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach
por: Kahnert, Kathrin, et al.
Publicado: (2018)

Spirometric testing on World COPD Day
por: Grzetic-Romcevic, Tanja, et al.
Publicado: (2011)

Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort
por: Alter, Peter, et al.
Publicado: (2023)

Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
por: Kellerer, Christina, et al.
Publicado: (2021)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial
por: Beeh, Kai M, et al.
Publicado: (2013)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
por: Calverley, Peter M A, et al.
Publicado: (2022)

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
por: Beeh, Kai-Michael, et al.
Publicado: (2009)

Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort
por: Kahnert, Kathrin, et al.
Publicado: (2017)

Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study
por: Mahler, Donald A, et al.
Publicado: (2023)

Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap
por: Nelsen, Linda M., et al.
Publicado: (2019)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET
por: Alter, Peter, et al.
Publicado: (2022)

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD
por: Lamprecht, Bernd, et al.
Publicado: (2011)

Mortality and readmission risk for hospitalised patients with acute exacerbation of COPD with and without spirometric obstruction: a longitudinal observational study in China
por: Ren, Xiaoxia, et al.
Publicado: (2023)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
por: Vestbo, Jørgen, et al.
Publicado: (2019)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study
por: Karrasch, Stefan, et al.
Publicado: (2016)

Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care
por: Rothnie, Kieran J, et al.
Publicado: (2017)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019)

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
por: Calverley, Peter MA, et al.
Publicado: (2019)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
por: Koch, Andrea, et al.
Publicado: (2017)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n9jqn1nnvfqas5dtliod9cje07